Philips is strengthening its relationship with Italy’s Agnelli family, with the family’s investment company Exor gaining the ability to increase its stake in the Dutch health-technology group to as much as 22%.
The agreement represents a renewed vote of confidence in Philips as the company continues its recovery from one of the most difficult periods in its recent history.
Exor originally became Philips’ largest shareholder in 2023, acquiring a 15.1% stake at a time when the Dutch company was dealing with the fallout from a major recall of sleep-apnea devices. Under the updated agreement, Exor will have greater flexibility to increase its ownership, reinforcing the long-term relationship between the two companies.
The development is important not simply because of the additional shares Exor could acquire. It also signals that one of Europe’s most influential investment families continues to see strategic value in Philips despite the challenges that remain.
Exor’s Original Philips Bet
When Exor first invested in Philips in August 2023, the decision carried considerable risk.
Philips was still dealing with the consequences of its Respironics recall, which involved millions of sleep-apnea and respiratory-care devices. The recall had triggered regulatory scrutiny, litigation and significant financial uncertainty.
Exor nevertheless committed about €2.6 billion to acquire its initial stake, making it Philips’ largest shareholder. The investment was widely interpreted as a long-term vote of confidence in the company’s transformation into a focused health-technology business.
The bet has so far produced a positive outcome.
Philips shares have gained nearly 25% since Exor first became its largest shareholder, according to Reuters, although the company’s recovery has not been smooth.
The latest agreement suggests Exor believes there is still additional value to unlock.
Exor Could Increase Stake to 22%
Under the updated arrangement, Exor can increase its ownership in Philips to as much as 22%.
That does not necessarily mean Exor will immediately buy the additional shares.
Instead, the agreement gives the investment company greater flexibility to increase its exposure if it believes Philips’ valuation and long-term prospects justify additional investment.
That distinction matters.
Exor has previously increased its Philips position gradually. In 2024, the Agnelli investment company raised its holding to 17.51%, and by March 2025 it had increased the stake again to 18.7%.
The latest agreement therefore appears to extend a relationship that has already developed over several years.
A Sign of Confidence in Philips’ Recovery
The strongest message from the deal is confidence.
Philips has spent several years trying to move beyond the Respironics crisis and rebuild its reputation with regulators, customers and investors.
The company has been restructuring its portfolio around health technology, including medical imaging, patient monitoring, image-guided therapy and connected healthcare products.
That transformation has become increasingly visible in Philips’ recent business updates.
In July, Philips reported solid comparable sales growth for the second quarter and reiterated its full-year sales outlook. The company also increased its adjusted EBITA and free-cash-flow outlook, partly reflecting a US tariff refund.
Those improvements provide an important backdrop to Exor’s decision.
The investment case is no longer based solely on the hope that Philips will survive its recall problems. It increasingly depends on whether the company can build a more profitable and technologically advanced healthcare business.
Philips Is Becoming More Focused on Healthcare
One of the biggest changes at Philips over the past several years has been the company’s strategic transformation.
Philips once operated across a much broader range of consumer and industrial businesses. Today, healthcare technology is at the center of its strategy.
Its portfolio includes medical imaging equipment, ultrasound systems, patient monitoring technologies and image-guided therapy.
The company is also increasingly incorporating artificial intelligence into healthcare products.
In July, Philips introduced the Alturion ultrasound system with AI-powered workflows designed for high-volume clinical environments. The company has also highlighted AI’s growing role in helping clinicians save time and improve healthcare delivery.
That creates a potentially attractive long-term market.
Healthcare systems around the world are facing rising demand while also dealing with shortages of medical professionals and pressure to control costs.
Technology that can make diagnosis and treatment more efficient could therefore become increasingly valuable.
China Remains a Weak Point
The bullish story, however, has a significant weakness: China.
Philips has faced weak sales in China, which has affected investor sentiment and limited some of the gains generated by its recovery.
Reuters previously reported that Philips shares lost part of their earlier rally as weak Chinese sales became a concern.
China remains an important healthcare market, and weakness there can have a meaningful impact on Philips’ growth.
The company therefore needs to demonstrate that stronger performance in other regions can compensate for continued pressure in China.
For Exor, that is one of the central risks associated with increasing its exposure.
The Recall Problem Has Not Simply Disappeared
Another risk is assuming that the Respironics crisis is completely finished.
Philips has made substantial progress in addressing the consequences of the recall, including reaching a settlement with the US government over sleep-apnea devices.
But regulatory and legal issues surrounding medical devices can remain complicated for years.
The recall damaged Philips’ reputation and forced the company to devote significant financial and managerial resources to resolving the consequences.
The company’s future performance will partly depend on whether investors can finally treat those problems as legacy issues rather than ongoing threats.
Why Exor Is Interested
Exor’s decision makes more sense when viewed through its broader investment strategy.
The Agnelli family’s investment company has historically held major positions in industrial, automotive, luxury, media, technology and healthcare-related businesses.
Its investment philosophy generally favors substantial, long-term holdings rather than short-term trading positions.
Philips fits that approach because healthcare technology is a large global market with long-term structural demand.
Exor does not need Philips to produce spectacular growth every quarter.
The more relevant question is whether Philips can steadily improve margins, increase free cash flow and build valuable technology platforms over many years.
The Strategic Relationship Could Matter
A larger shareholder position can also create a closer relationship between Philips and Exor.
That does not automatically mean Exor will seek operational control.
The company has previously positioned its Philips investment as a long-term partnership and has not indicated that it intends to take over the Dutch healthcare company.
But a shareholder with the ability to own more than one-fifth of the company naturally carries significant influence.
That could become important if Philips considers major acquisitions, portfolio changes or other strategic decisions.
A strong long-term shareholder can also provide stability during periods of market volatility.
Investors Will Watch Execution
The next challenge for Philips is execution.
The company needs to translate its improved financial performance into sustainable growth.
That means maintaining innovation, controlling costs, improving profitability and successfully integrating AI into its healthcare products.
The company also needs to navigate geopolitical risks, tariffs and changing healthcare budgets around the world.
Its recent results suggest that progress is being made, but investors will want to see that progress continue.
Exor’s increased flexibility therefore represents confidence—but not a guarantee of future success.
What the Deal Means for Philips
For Philips, the agreement provides another important signal to the market.
Having a major long-term shareholder willing to potentially increase its stake can reinforce investor confidence, particularly after years of uncertainty surrounding the company.
It also demonstrates that Exor still believes Philips has room to grow.
The company’s shares have already recovered significantly from their lows, but the Agnelli family’s willingness to remain closely involved suggests it sees further potential.
Looking Ahead
The updated relationship between Philips and Exor marks another stage in the Dutch healthcare company’s recovery.
Exor’s ability to raise its stake from its existing position to as much as 22% gives the Agnelli family’s investment company greater exposure to Philips and strengthens its position as the company’s largest shareholder.
The move comes after several years in which Philips has attempted to repair the damage caused by the Respironics recall while reshaping itself into a more focused health-technology business.
There are still significant risks. Weakness in China, regulatory uncertainty and the difficulty of generating consistent growth in global healthcare markets could all weigh on the company.
But Philips is now operating from a stronger position than it was when Exor first invested.
Its recent financial performance has improved, its portfolio is increasingly focused on healthcare technology and AI is creating new opportunities across medical imaging, diagnostics and clinical workflows.
For the Agnelli family, the decision to deepen its relationship with Philips is therefore a calculated long-term bet.
For Philips, it provides something equally valuable: a major shareholder that appears willing to remain invested in the company’s transformation rather than treating the recovery as a short-term trade.
The next test will be whether Philips can turn that confidence into sustained earnings growth and stronger returns for all shareholders.
